Search

Your search keyword '"Haynes, Annette"' showing total 180 results
Start Over Author "Haynes, Annette"
180 results on '"Haynes, Annette"'

1. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

Author

Facon, Thierry, Dimopoulos, Meletios A., Dispenzieri, Angela, Catalano, John V., Belch, Andrew, Cavo, Michele, Pinto, Antonello, Weisel, Katja, Ludwig, Heinz, Bahlis, Nizar J., Banos, Anne, Tiab, Mourad, Delforge, Michel, Cavenagh, Jamie D., Geraldes, Catarina, Lee, Je-Jung, Chen, Christine, Oriol, Albert, De La Rubia, Javier, White, Darrell, Binder, Daniel, Lu, Jin, Anderson, Kenneth C., Moreau, Philippe, Attal, Michel, Perrot, Aurore, Arnulf, Bertrand, Qiu, Lugui, Roussel, Murielle, Boyle, Eileen, Manier, Salomon, Mohty, Mohamad, Avet-Loiseau, Herve, Leleu, Xavier, Ervin-Haynes, Annette, Chen, Guang, Houck, Vanessa, Benboubker, Lotfi, and Hulin, Cyrille

Published
2018
Full Text
View/download PDF

5. ABCL-339: Clinical Activity of Loncastuximab Tesirine (Lonca) Plus Ibrutinib in Non-Hodgkin Lymphoma: Updated LOTIS-3 Phase 1 Results

Author

Janakiram, Murali, primary, Depaus, Julien, additional, Wagner-Johnston, Nina, additional, Zinzani, Pier Luigi, additional, Phillips, Tycel J., additional, Maly, Joseph, additional, Ferrari, Silvia, additional, Bryan, Locke J., additional, Delwail, Vincent, additional, de Guibert, Sophie, additional, Tani, Monica, additional, Dai, Vivian, additional, Havenith, Karin, additional, Boni, Joseph, additional, He, Xiaomin, additional, Ervin-Haynes, Annette, additional, and Carlo-Stella, Carmelo, additional

Published
2021
Full Text
View/download PDF

6. Poster: ABCL-339: Clinical Activity of Loncastuximab Tesirine (Lonca) Plus Ibrutinib in Non-Hodgkin Lymphoma: Updated LOTIS-3 Phase 1 Results

Author

Janakiram, Murali, primary, Depaus, Julien, additional, Wagner-Johnston, Nina, additional, Zinzani, Pier Luigi, additional, Phillips, Tycel J., additional, Maly, Joseph, additional, Ferrari, Silvia, additional, Bryan, Locke J., additional, Delwail, Vincent, additional, De Guibert, Sophie, additional, Tani, Monica, additional, Dai, Vivian, additional, Havenith, Karin, additional, Boni, Joseph, additional, He, Xiaomin, additional, Ervin-Haynes, Annette, additional, and Carlo-Stella, Carmelo, additional

Published
2021
Full Text
View/download PDF

7. Trial in Progress: An Open Label Phase I/II, Multicenter Study Evaluating Safety, Pharmacokinetics and Efficacy of S65487, a BCL-2 Inhibitor Combined with Azacitidine in Adults with Previously Untreated Acute Myeloid Leukemia Ineligible for Intensive Treatment

Author

Pierola, Ana Alfonso, De Botton, Stephane, Jang, Jun Ho, Campbell, Victoria, O'Nions, Jenny, Calbacho, Maria, Ervin-Haynes, Annette L., Keagle, Kristen, Maillard, Aline, Beneton, Maud, Romagnoli, Mathilde, and Broniscer, Alberto

Published
2023
Full Text
View/download PDF

8. Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

Author

Benboubker, Lotfi, Dimopoulos, Meletios A., Dispenzieri, Angela, Catalano, John, Belch, Andrew R., Cavo, Michele, Pinto, Antonello, Weisel, Katja, Ludwig, Heinz, Bahlis, Nizar, Banos, Anne, Tiab, Mourad, Delforge, Michel, Cavenagh, Jamie, Geraldes, Catarina, Lee, Je-Jung, Chen, Christine, Oriol, Albert, de la Rubia, Javier, Qiu, Lugui, White, Darrell J., Binder, Daniel, Anderson, Kenneth, Fermand, Jean-Paul, Moreau, Philippe, Attal, Michel, Knight, Robert, Chen, Guang, Van Oostendorp, Jason, Jacques, Christian, Ervin-Haynes, Annette, Avet-Loiseau, Hervé, Hulin, Cyrille, and Facon, Thierry

Published
2014
Full Text
View/download PDF

12. LETTERS

Author

Haynes, Annette

Published
2010

15. Contributors

Author

Arce, Ellen, Berger, Sarah J., Berta, Janine Wong, Burke, Darlene M., Close, Jacqueline Fitzgerald, de Haas-Rowland, Natalie B., Dineen, Kelly K., Dirks, Joni L., Etland, Caroline, Freeman, Regi, Géilinas, Céiline, Graham, Julie-Kathryn, Halter, Margaret Jordan, Haynes, Annette, Henry, Patricia, Hutchins, Susie, Jenkins, Misty, Larsen, Amy, Lee, Roy, Lewis, Cynthia A., Lough, Mary E., Mondor, Eugene E., Myers, Robyn, Oro, Gabriela, Redwantz, Tara Jean, Sanchez, Kimberly, Sandoval, Cass Piper, Scotto, Carrie J., Seigel, Jennifer, Shafer, Teresa J., Stacy, Kathleen M., Suarez, Carol Ann, Urden, Linda D., Voltz, Melissa, Waters, Julie M., Williams-Taylor, Schawnté P., Wilson, Carrie M., Winnie, Kathrine Anne, Winterbottom, Fiona, Atwood, Angela G., and Logan, Laura

Published
2022
Full Text
View/download PDF

16. First-in-human, dose-escalation, phase (ph) I trial to evaluate safety of anti-Axl antibody-drug conjugate (ADC) enapotamab vedotin (EnaV) in solid tumors.

Author

Ameratunga, Malaka, primary, Harvey, R Donald, additional, Mau-Sørensen, Morten, additional, Thistlethwaite, Fiona, additional, Forssmann, Ulf, additional, Gupta, Manish, additional, Johannsdottir, Hrefna, additional, Ramirez-Andersen, Terrie, additional, Bohlbro, Mika Linette, additional, Losic, Nedjad, additional, Ervin-Haynes, Annette L., additional, Lopez, Juanita Suzanne, additional, and Vergote, Ignace, additional

Published
2019
Full Text
View/download PDF

18. Final analysis of overall survival from the first trial

Author

Facon, Thierry Dimopoulos, Meletios A. Dispenzieri, Angela and Catalano, John V. Belch, Andrew Cavo, Michele Pinto, Antonello Weisel, Katja Ludwig, Heinz Bahlis, Nizar J. and Banos, Anne Tiab, Mourad Delforge, Michel Cavenagh, Jamie D. and Geraldes, Catarina Lee, Je-Jung Chen, Christine Oriol, Albert De La Rubia, Javier White, Darrell Binder, Daniel and Lu, Jin Anderson, Kenneth C. Moreau, Philippe Attal, Michel and Fermand, Jean-Paul Avet-Loiseau, Herve Ervin-Haynes, Annette and Chen, Guang Houck, Vanessa Hulin, Cyrille Benboubker, Lofti

Subjects
Health Sciences, Επιστήμες Υγείας
Published
2016

20. A phase 1/2 study of durvalumab (DURVA) in combination with lenalidomide (LEN) with or without dexamethasone (DEX) in patients (pts) with newly diagnosed multiple myeloma (NDMM).

Author

Lonial, Sagar, primary, Oriol, Albert, additional, Mateos, Maria-Victoria, additional, Rodriguez-Otero, Paula, additional, Bahlis, Nizar J., additional, Bensinger, William, additional, Porkka, Kimmo, additional, Van De Donk, Niels, additional, Yiu, Wai, additional, Di Casoli, Carl, additional, Ervin-Haynes, Annette L., additional, Zaki, Mohamed H., additional, and Vangsted, Annette, additional

Published
2017
Full Text
View/download PDF

22. Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial

Author

Lu, Jin, primary, Lee, Jae H., additional, Huang, Shang-Yi, additional, Qiu, Lugui, additional, Lee, Je-Jung, additional, Liu, Ting, additional, Yoon, Sung-Soo, additional, Kim, Kihyun, additional, Shen, Zhi X., additional, Eom, Hyeon S., additional, Chen, Wen M., additional, Min, Chang K., additional, Kim, Hyo J., additional, Lee, Jeong O., additional, Kwak, Jae Y., additional, Yiu, Wai, additional, Chen, Guang, additional, Ervin-Haynes, Annette, additional, Hulin, Cyrille, additional, and Facon, Thierry, additional

Published
2017
Full Text
View/download PDF

23. Final Analysis of Overall Survival from the First Trial

Author

Facon, Thierry, primary, Dimopoulos, Meletios A, additional, Dispenzieri, Angela, additional, Catalano, John V., additional, Belch, Andrew, additional, Cavo, Michele, additional, Pinto, Antonello, additional, Weisel, Katja, additional, Ludwig, Heinz, additional, Bahlis, Nizar J., additional, Banos, Anne, additional, Tiab, Mourad, additional, Delforge, Michel, additional, Cavenagh, Jamie D., additional, Geraldes, Catarina, additional, Lee, Je-Jung, additional, Chen, Christine, additional, Oriol, Albert, additional, De La Rubia, Javier, additional, White, Darrell, additional, Binder, Daniel, additional, Lu, Jin, additional, Anderson, Kenneth C., additional, Moreau, Philippe, additional, Attal, Michel, additional, Fermand, Jean-Paul, additional, Avet-Loiseau, Herve, additional, Ervin-Haynes, Annette, additional, Chen, Guang, additional, Houck, Vanessa, additional, Hulin, Cyrille, additional, and Benboubker, Lofti, additional

Published
2016
Full Text
View/download PDF

24. A Frailty Scale Predicts Outcomes of Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone on the First Trial

Author

Facon, Thierry Hulin, Cyrille Dimopoulos, Meletios A. Belch, Andrew Meuleman, Nathalie Mohty, Mohamad Chen, Wen-Ming and Kim, Kihyun Zamagni, Elena Rodriguez-Otero, Paula Renwick, William Rose, Christian Tempescul, Adrian Palumbo, Antonio and Guo, Shien Sturniolo, Michael Ervin-Haynes, Annette and Fermand, Jean-Paul

Published
2015

26. Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.

Author

UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Hulin, Cyrille, Belch, Andrew, Shustik, Chaim, Petrucci, Maria Teresa, Dührsen, Ulrich, Lu, Jin, Song, Kevin, Rodon, Philippe, Pégourié, Brigitte, Garderet, Laurent, Hunter, Hannah, Azais, Isabelle, Eek, Richard, Gisslinger, Heinz, Macro, Margaret, Dakhil, Shaker, Goncalves, Cristina, LeBlanc, Richard, Romeril, Ken, Royer, Bruno, Doyen, Chantal, Leleu, Xavier, Offner, Fritz, Leupin, Nicolas, Houck, Vanessa, Chen, Guang, Ervin-Haynes, Annette, Dimopoulos, Meletios A, Facon, Thierry, UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Hulin, Cyrille, Belch, Andrew, Shustik, Chaim, Petrucci, Maria Teresa, Dührsen, Ulrich, Lu, Jin, Song, Kevin, Rodon, Philippe, Pégourié, Brigitte, Garderet, Laurent, Hunter, Hannah, Azais, Isabelle, Eek, Richard, Gisslinger, Heinz, Macro, Margaret, Dakhil, Shaker, Goncalves, Cristina, LeBlanc, Richard, Romeril, Ken, Royer, Bruno, Doyen, Chantal, Leleu, Xavier, Offner, Fritz, Leupin, Nicolas, Houck, Vanessa, Chen, Guang, Ervin-Haynes, Annette, Dimopoulos, Meletios A, and Facon, Thierry

Abstract

Purpose This analysis of the FIRST trial in patients with newly diagnosed multiple myeloma (MM) ineligible for stem-cell transplantation examined updated outcomes and impact of patient age. Patients and Methods Patients with untreated symptomatic MM were randomly assigned at a one-to-one-to-one ratio to lenalidomide plus low-dose dexamethasone until disease progression (Rd continuous), Rd for 72 weeks (18 cycles; Rd18), or melphalan, prednisone, and thalidomide (MPT; 72 weeks), stratified by age (≤ 75 v > 75 years), disease stage (International Staging System stage I/II v III), and country. The primary end point was progression-free survival. Rd continuous and MPT were primary comparators. Results Between August 21, 2008, and March 7, 2011, 1,623 patients were enrolled (Rd continuous, n = 535; Rd18, n = 541; MPT, n = 547), including 567 (35%) age older than 75 years. Higher rates of advanced-stage disease and renal impairment were observed in patients older than 75 versus 75 years of age or younger. Rd continuous reduced the risk of progression or death compared with MPT by 31% (hazard ratio [HR], 0.69; 95% CI, 0.59 to 0.80; P < .001) overall, 36% (HR, 0.64; 95% CI, 0.53 to 0.77; P < .001) in patients age 75 years or younger, and 20% (HR, 0.80; 95% CI, 0.62 to 1.03; P = .084) in those age older than 75 years. Median overall survival was longer with Rd continuous than with MPT, including a 14-month difference in patients age older than 75 years. Progression-free survival with Rd18 was similar to that with MPT, and overall survival with Rd18 was marginally inferior to that with Rd continuous. Rates of grade 3 to 4 treatment-emergent adverse events were similar for Rd continuous-treated patients age 75 years or older and those age older than 75 years; however, older patients had more frequent lenalidomide dose reductions. Conclusion Results support Rd continuous treatment as a new standard of care for stem-cell transplantation-ineligible patients with newly diagnosed M

Published
2016

28. Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial

Author

Hulin, Cyrille, primary, Belch, Andrew, additional, Shustik, Chaim, additional, Petrucci, Maria Teresa, additional, Dührsen, Ulrich, additional, Lu, Jin, additional, Song, Kevin, additional, Rodon, Philippe, additional, Pégourié, Brigitte, additional, Garderet, Laurent, additional, Hunter, Hannah, additional, Azais, Isabelle, additional, Eek, Richard, additional, Gisslinger, Heinz, additional, Macro, Margaret, additional, Dakhil, Shaker, additional, Goncalves, Cristina, additional, LeBlanc, Richard, additional, Romeril, Ken, additional, Royer, Bruno, additional, Doyen, Chantal, additional, Leleu, Xavier, additional, Offner, Fritz, additional, Leupin, Nicolas, additional, Houck, Vanessa, additional, Chen, Guang, additional, Ervin-Haynes, Annette, additional, Dimopoulos, Meletios A., additional, and Facon, Thierry, additional

Published
2016
Full Text
View/download PDF

30. Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study

Author

Suzuki, Kenshi, primary, Shinagawa, Atsushi, additional, Uchida, Toshiki, additional, Taniwaki, Masafumi, additional, Hirata, Hirokazu, additional, Ishizawa, Kenichi, additional, Matsue, Kosei, additional, Ogawa, Yoshiaki, additional, Shimizu, Takayuki, additional, Otsuka, Maki, additional, Matsumoto, Morio, additional, Iida, Shinsuke, additional, Terui, Yasuhito, additional, Matsumura, Itaru, additional, Ikeda, Takashi, additional, Takezako, Naoki, additional, Ogaki, Yumi, additional, Midorikawa, Shuichi, additional, Houck, Vanessa, additional, Ervin-Haynes, Annette, additional, and Chou, Takaaki, additional

Published
2016
Full Text
View/download PDF

31. Continuous Treatment with Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the First Trial

Author

Lu, Jin, primary, Lee, Jae Hoon, additional, Huang, Shang-Yi, additional, Qiu, Lugui, additional, Lee, Je-Jung, additional, Liu, Ting, additional, Yoon, Sung-Soo, additional, Kim, Kihyun, additional, Shen, Zhi Xiang, additional, Eom, HyeonSeok, additional, Chen, Wenming, additional, Min, Chang-Ki, additional, Kim, Hyo Jung, additional, Lee, Jeong Ok, additional, Kwak, Jae Yong, additional, Yiu, Wai, additional, Chen, Guang, additional, Ervin Haynes, Annette, additional, Hulin, Cyrille, additional, and Facon, Thierry, additional

Published
2015
Full Text
View/download PDF

32. A Frailty Scale Predicts Outcomes of Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone on the First Trial

Author

Facon, Thierry, primary, Hulin, Cyrille, additional, Dimopoulos, Meletios A., additional, Belch, Andrew, additional, Meuleman, Nathalie, additional, Mohty, Mohamad, additional, Chen, Wen-Ming, additional, Kim, Kihyun, additional, Zamagni, Elena, additional, Rodriguez-Otero, Paula, additional, Renwick, William, additional, Rose, Christian, additional, Tempescul, Adrian, additional, Palumbo, Antonio, additional, Guo, Shien, additional, Sturniolo, Michael, additional, Ervin-Haynes, Annette, additional, and Fermand, Jean-Paul, additional

Published
2015
Full Text
View/download PDF

33. Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) Trial

Author

Avet-Loiseau, Herve, primary, Hulin, Cyrille, additional, Benboubker, Lofti, additional, Dimopoulos, Meletios A., additional, Belch, Andrew, additional, Reece, Donna, additional, Catalano, John, additional, Pinto, Antonio, additional, Ludwig, Heinz, additional, Bahlis, Nizar J, additional, Cavo, Michele, additional, Attal, Michel, additional, Moreau, Philippe, additional, Qiu, Lugui, additional, LeBlanc, Richard, additional, Schots, Rik, additional, Rajkumar, S. Vincent, additional, Marek, Jennifer, additional, Chen, Guang, additional, Yiu, Wai, additional, Ervin-Haynes, Annette, additional, and Facon, Thierry, additional

Published
2015
Full Text
View/download PDF

34. Contributors

Author

Blach, Deanne A., Burke, Darlene M., Carlson, Beverly, Close, Jacqueline F., Dineen, Kelly K., Dirks, Joni L., Etland, Caroline, Fitzsimmons, Lorraine, Gélinas, Céline, Goldvarg-Abud, Inna, Halter, Margaret Jordan, Hartley, Christine, Haynes, Annette, Hutchins, Susie, Januszewicz, Lourdes, Jenkins, Misty, Lewis, Cynthia A., Lough, Mary E., Maiden, Jeanne M., Mauldin, Kasuen, Mayer, Barbara, Mondor, Eugene E., Myers, Robyn, O’Brien, Denise, Scotto, Carrie J., Seigel, Jennifer, Shafer, Teresa J., Stacy, Kathleen M., Suarez, Carol A., Urden, Linda D., Waters, Julie M., Williams-Taylor, Schawnté, Wilson, Carrie M., and Winterbottom, Fiona

Published
2018
Full Text
View/download PDF

35. Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone.

Author

Vogl, Dan T., Delforge, Michel, Song, Kevin, Guo, Shien, Gibson, Craig J., Ervin-Haynes, Annette, and Facon, Thierry

Subjects
QUALITY of life, DEXAMETHASONE, MULTIPLE myeloma, B cell lymphoma, CANCER patients
Abstract

The FIRST trial demonstrated that continuous therapy with lenalidomide and dexamethasone (Rd) prolongs overall survival (OS) and improves health-related quality of life (HRQoL) during the first 18 months of therapy in newly diagnosed multiple myeloma (NDMM) patients. However, patient-reported HRQoL data were not collected after 18 months. We therefore estimated HRQoL scores based on time-varying data collected during progression-free follow-up after 18 months. During the initial 18 months of Rd, observed changes from baseline were within the 95% confidence interval of the predictive models at 33 of 35 time points across 7 HRQoL scores. Predicted scores after 18 months of therapy showed that observed HRQoL improvements during therapy were maintained or improved. Therefore, the survival gain observed with Rd does not come at a cost of declining HRQoL during continuous therapy beyond 18 months, supporting long-term Rd as a standard of care for initial myeloma therapy. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

38. FIRST study: Updated overall survival (OS) in stem cell transplant (SCT)-ineligible newly diagnosed multiple myeloma (NDMM) patients (pts) treated with continuous lenalidomide plus low-dose dexamethasone (Rd) vs melphalan, prednisone, and thalidomide (MPT).

Author

Facon, Thierry, primary, Hulin, Cyrille, additional, Dimopoulos, Meletios A., additional, Belch, Andrew, additional, Reece, Donna Ellen, additional, Catalano, John V., additional, Pinto, Antonio, additional, Ludwig, Heinz, additional, Bahlis, Nizar J., additional, Cavo, Michele, additional, Moreau, Philippe, additional, Qiu, Lugui, additional, LeBlanc, Richard, additional, Schots, Rik, additional, Rajkumar, S. Vincent, additional, Marek, Jennifer, additional, Chen, Guang, additional, and Ervin-Haynes, Annette L., additional

Published
2015
Full Text
View/download PDF

39. Phase 2 Study of Lenalidomide in Combination with Low-Dose Dexamethasone in Japanese Transplantation-Ineligible Newly-Diagnosed Multiple Myeloma Patients

Author

Chou, Takaaki, primary, Shinagawa, Atsushi, additional, Uchida, Toshiki, additional, Taniwaki, Masafumi, additional, Hirata, Hirokazu, additional, Ishizawa, Kenichi, additional, Matsue, Kosei, additional, Ogawa, Yoshiaki, additional, Shimizu, Takayuki, additional, Otsuka, Maki, additional, Matsumoto, Morio, additional, Iida, Shinsuke, additional, Terui, Yasuhito, additional, Matsumura, Itaru, additional, Ikeda, Takashi, additional, Takezako, Naoki, additional, Ogaki, Yumi, additional, Midorikawa, Shuichi, additional, Houck, Vanessa, additional, Ervin-Haynes, Annette, additional, and Suzuki, Kenshi, additional

Published
2014
Full Text
View/download PDF

40. Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone (Rd): The First Trial

Author

Hulin, Cyrille, primary, Facon, Thierry, additional, Shustik, Chaim, additional, Belch, Andrew, additional, Petrucci, Maria Teresa, additional, Dührsen, Ulrich, additional, Lu, Jin, additional, Song, Kevin, additional, Rodon, Philippe, additional, Pegourie, Brigitte, additional, Garderet, Laurent, additional, Hunter, Hannah, additional, Azais, Isabelle, additional, Eek, Richard, additional, Macro, Margaret, additional, Dakhil, Shaker, additional, Houck, Vanessa, additional, Chen, Guang, additional, Ervin-Haynes, Annette, additional, and Offner, Fritz, additional

Published
2014
Full Text
View/download PDF

41. Impact of Renal Impairment (RI) on Outcomes after Treatment (Tx) with Lenalidomide and Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): First Trial Results

Author

Dimopoulos, Meletios A., primary, Cheung, Matthew C, additional, Roussel, Murielle, additional, Liu, Ting, additional, Gamberi, Barbara, additional, Kolb, Brigitte, additional, Derigs, H. Guenter, additional, Eom, Hyeon Seok, additional, Belhadj, Karim, additional, Lenain, Pascal, additional, van der Jagt, Richard H., additional, Rigaudeau, Sophie, additional, Dib, Mamoun, additional, Hall, Rachel, additional, Jaccard, Arnaud, additional, Tosikyan, Axel, additional, Karlin, Lionel, additional, Bensinger, William, additional, Schots, Rik, additional, Chen, Guang, additional, Marek, Jennifer, additional, Ervin-Haynes, Annette, additional, and Facon, Thierry, additional

Published
2014
Full Text
View/download PDF

42. Healthcare Resource Utilization Trends over Time with Continuous Lenalidomide Treatment (Tx) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM)

Author

Weisel, Katja, primary, Vogl, Dan T., additional, Delforge, Michel, additional, Song, Kevin, additional, Dimopoulos, Meletios, additional, Cavenagh, Jamie, additional, Hulin, Cyrille, additional, Rodon, Philippe, additional, Arnulf, Bertrand, additional, Foá, Robin, additional, Oriol, Albert, additional, Guo, Shien, additional, Monzini, Mara Silvia, additional, Van Oostendorp, Jason, additional, Ervin-Haynes, Annette, additional, and Facon, Thierry, additional

Published
2014
Full Text
View/download PDF

43. Impact of Response Quality on Survival Outcomes in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Results from the First Trial

Author

Bahlis, Nizar J, primary, Corso, Alessandro, additional, Mugge, Lars-Olof, additional, Shen, Zhi-Xiang, additional, Desjardins, Pierre, additional, Stoppa, Anne-Marie, additional, Decaux, Olivier, additional, De Revel, Thierry, additional, Granell, Miquel, additional, Marit, Gerald, additional, Nahi, Hareth, additional, Demuynck, Hilde, additional, Huang, Shang-Yi, additional, Basu, Supratik, additional, Guthrie, Troy H., additional, Ervin-Haynes, Annette, additional, Leupin, Nicolas, additional, Marek, Jennifer, additional, Chen, Guang, additional, and Facon, Thierry, additional

Published
2014
Full Text
View/download PDF

44. Health-related quality of life (HRQOL) in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Results from the first trial.

Author

Delforge, Michel, primary, Minuk, Leonard, additional, Eisenmann, Jean-Claude, additional, Arnulf, Bertrand, additional, Canepa, Letizia, additional, Fragasso, Alberto, additional, Leyvraz, Serge, additional, Langer, Christian, additional, Ezaydi, Yousef, additional, Vogl, Dan T., additional, Giraldo-Castellano, Pilar, additional, Yoon, Sung-Soo, additional, Martins, Angelo, additional, Zarnitsky, Charles, additional, Escoffre Barbe, Martine, additional, Lemieux, Bernard, additional, Proskorovsky, Irina, additional, Ervin-Haynes, Annette L., additional, Houck, Vanessa, additional, and Facon, Thierry, additional

Published
2014
Full Text
View/download PDF

45. Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT)

Author

Facon, Thierry, primary, Dimopoulos, Meletios A., additional, Dispenzieri, Angela, additional, Catalano, John V., additional, Belch, Andrew R, additional, Hulin, Cyrille, additional, Cavo, Michele, additional, Pinto, Antonella, additional, Weisel, Katja, additional, Ludwig, Heinz, additional, Bahlis, Nizar J., additional, Banos, Anne, additional, Tiab, Mourad, additional, Delforge, Michel, additional, Cavenagh, James D, additional, Geraldes, Catarina, additional, Lee, Je-Jung, additional, Chen, Christine I., additional, Oriol, Albert, additional, De La Rubia, Javier, additional, Qiu, Lugui, additional, White, Darrell J., additional, Binder, Daniel, additional, Anderson, Kenneth C., additional, Moreau, Philippe, additional, Attal, Michel, additional, Knight, Robert, additional, Chen, Guang, additional, Van Oostendorp, Jason, additional, Jacques, Christian J., additional, Ervin-Haynes, Annette, additional, and Benboubker, Lofti, additional

Published
2013
Full Text
View/download PDF

46. Phase II Multicenter Study of the Safety and Efficacy of Single-Agent Lenalidomide in Subjects with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Follow-up Analysis of the NHL-003 Study.

Author

Zinzani, Pier Luigi, primary, Vose, Julie M, additional, Czuczman, Myron S., additional, Reeder, Craig, additional, Haioun, Corinne, additional, Polikoff, Jonathan, additional, Tilly, Herve, additional, Pietronigro, Dennis, additional, Ervin-Haynes, Annette, additional, Li, Ju, additional, and Witzig, Thomas E., additional

Published
2012
Full Text
View/download PDF

47. Contributors

Author

Berta, Janine Wong, Burke, Darlene M., Carlson, Beverly A., Close, Jacqueline F., Dineen, Kelly K., Dirks, Joni L., Etland, Caroline, Fitzsimmons, Lorraine, Géilinas, Céiline, Halter, Margaret Jordan, Haynes, Annette, Januszewicz, Lourdes, Jenkins, Misty, Lough, Mary E., Maiden, Jeanne, Mauldin, Kasuen, Mayer, Barbara, Mondor, Eugene, Myers, Robyn, Scotto, Carrie J., Seigel, Jennifer, Stacy, Kathleen M., Suarez, Carol Ann, Urden, Linda D., Waters, Julie M., Wilson, Carrie M., and Winterbottom, Fiona

Published
2020
Full Text
View/download PDF

48. Single-Agent Lenalidomide for Patients with Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma Who Had Received Prior Stem Cell Transplant.

Author

Vose, Julie M., primary, Habermann, Thomas, additional, Czuczman, Myron S, additional, Zinzani, Pier Luigi, additional, Reeder, Craig B., additional, Tuscano, Joseph, additional, Lossos, Izidore S, additional, Pietronigro, Dennis, additional, Ervin-Haynes, Annette, additional, and Witzig, Thomas, additional

Published
2009
Full Text
View/download PDF

49. Durable Responses After Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory (R/R) Aggressive Non-Hodgkin's Lymphoma (a-NHL): Results From An International Phase 2 Study (CC-5013-NHL-003).

Author

Witzig, Thomas E, primary, Vose, Julie M., additional, Zinzani, Pier Luigi, additional, Reeder, Craig B., additional, Buckstein, Rena, additional, Polikoff, Jonathan, additional, Guo, Pingshan, additional, Pietronigro, Dennis, additional, Ervin-Haynes, Annette, additional, and Czuczman, Myron S, additional

Published
2009
Full Text
View/download PDF

50. Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Author

Witzig, Thomas E., primary, Wiernik, Peter H., additional, Moore, Timothy, additional, Reeder, Craig, additional, Cole, Craig, additional, Justice, Glen, additional, Kaplan, Henry, additional, Voralia, Michael, additional, Pietronigro, Dennis, additional, Takeshita, Kenichi, additional, Ervin-Haynes, Annette, additional, Zeldis, Jerome B., additional, and Vose, Julie M., additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results